Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial

AIMS: Schizophrenia is associated with cardiovascular co‐morbidity and a reduced life‐expectancy of up to 20 years. Antipsychotics are dopamine D(2) receptor antagonists and are the standard of medical care in schizophrenia, but the drugs are associated with severe metabolic side effects such as obe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Ishøy, Pelle L., Knop, Filip K., Broberg, Brian V., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Holst, Jens J., Glenthøj, Birte Y., Ebdrup, Bjørn H.
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299524/
https://ncbi.nlm.nih.gov/pubmed/27717222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12795
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars